secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001077183-23-000136
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance
---------------------------------------------------------------------------

- Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).
- Net loss decreased 50% to $19M; Adjusted EBITDA turned positive at $3M vs -$12M YoY.
- Raised FY23 revenue guidance to $585-592M (15-16% growth); Adj. EBITDA loss guidance improved to $4M-$1M loss.
- Cash and marketable securities $402M at quarter end.
- Adjusted Gross Profit Margin 44.2%, excluding amortization of acquired Inivata developed technology intangibles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/neo-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001077183-23-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer